Gender‐affirming hormone therapy for transgender and gender‐diverse adults in Australia

The document reviews gender-affirming hormone therapy (GAHT) for transgender and gender-diverse adults in Australia, highlighting the informed consent model's prevalence and high patient satisfaction. It details testosterone therapy for individuals assigned female at birth, noting physical changes and adverse effects like acne and androgenic alopecia, with limited data on treatments such as finasteride. Estradiol therapy for feminization involves monitoring serum levels and carries risks like venous thromboembolism, though modern regimens are safer. GAHT improves gender incongruence and mental health but increases cardiovascular risks, necessitating proactive management. Bone health concerns are addressed, with improvements seen post-therapy. Cancer screening should be anatomy-specific, with estradiol users having higher breast cancer rates than cisgender men. Individualized care and education are emphasized for safe and effective GAHT.